$ONCY Headlines Oncolytics prices offering at 14%

New Post Public Reply Private Reply Replies (0) Message Board

Jan 23, 2014 at 10:15 PM

$ONCY Headlines

Oncolytics prices offering at 14% discount 2:21 p.m. Feb. 20, 2013 - MarketWatch.com
Canada hot stocks : Oncolytics, Just Energy 12:37 p.m. Feb. 8, 2013 - MarketWatch.com
Oncolytics shares up on positive Reolysin results 8:59 a.m. Feb. 8, 2013 - MarketWatch.com
Oncolytics rises 27% after positive Phase III data 8:45 a.m. Dec. 13, 2012 - Steve Gelsi
Oncolytics Biotech up 27% in premarket 8:38 a.m. Dec. 13, 2012 - Steve Gelsi
Wednesday’s biggest gaining and declining stocks 3:18 p.m. Sept. 12, 2012 - MarketWatch
Tuesday's biggest stock gainers and decliners 4:24 p.m. June 5, 2007 - MarketWatch
Tuesday's biggest stock gainers and decliners 4:43 p.m. April 17, 2007 - Michael Baron
Oncolytics shares rise on data from Reolysin study 9:37 a.m. April 17, 2007 - Gabriel Madway
Oncolytics Biotech up 13% at $2.20 9:04 a.m. April 17, 2007 - Tomi Kilgore
Tuesday's biggest stock gainers and decliners 6:09 p.m. Feb. 6, 2007 - Michael Baron
Wednesday's biggest U.S. stock gainers and decliners 5:55 p.m. Jan. 3, 2007 - MarketWatch
Oncolytics Biotech gets U.K. approval for Reolysin trial 10:45 a.m. Jan. 3, 2007 - Gabriel Madway
Oncolytics Biotech shares up 4.3% at $2.18 10:38 a.m. Jan. 3, 2007 - Gabriel Madway
Oncolytics Biotech gets U.K. approval for Reolysin trial 10:38 a.m. Jan. 3, 2007 - Gabriel Madway
Friday's biggest stock gainers and decliners 2:07 p.m. Dec. 22, 2006 - MarketWatch
Oncolytics starts patient enrollment in Reolysin trial 11:00 a.m. Dec. 22, 2006 - Gabriel Madway
Oncolytics starts patient enrollment in Reolysin trial 10:50 a.m. Dec. 22, 2006 - Gabriel Madway
Oncolytics down 8.8% at $4.57 9:48 a.m. Dec. 13, 2005 - Tomi Kilgore
Oncolytics to issue 3.2 million unit private offering 6:49 a.m. Dec. 13, 2005 - Simon Kennedy

On the Road to Riches in Biotech 4:10 a.m. Dec. 28, 2013 - Barrons.com
A confused Needham maintains Buy rating on Oncolytics 11:54 a.m. Nov. 25, 2013 - Seeking Alpha
Oncolytics: One Drug To Treat Them All, Or A Complete Dud, Data Is Not Bad 12:51 a.m. Nov. 24, 2013 - Seeking Alpha
After premarket head fake, Oncolytics Biotech slides as investors parse results 10:51 a.m. Nov. 21, 2013 - Seeking Alpha
2 Small Speculative Biotech Plays Moving On News 9:55 a.m. Nov. 21, 2013 - Seeking Alpha
Oncolytics Biotech rallies on Reolysin results 8:32 a.m. Nov. 21, 2013 - Seeking Alpha
Oncolytics Biotech Announces Positive Top-Line Data from REO 018 Randomized Study of REOLYSIN 5:28 a.m. Nov. 21, 2013 - benzinga.com
Thursday’s Biggest Stock Losers: SGOC, VJET, and More 4:56 a.m. Nov. 21, 2013 - InvestorPlace.com
Oncolytics Announces Positive Phase 2 REOLYSIN Data 4:36 a.m. Oct. 28, 2013 - benzinga.com
Oncolytics Announces Progression Free Survival Data for Phase 2 REOLYSIN Study 4:43 a.m. Oct. 22, 2013 - benzinga.com
Encouraging Data on Oncolytics' Reolysin - Analyst Blog 4:40 p.m. Sept. 10, 2013 - Zacks.com
Five Highly Unusual Hot Stocks on the Move for Monday 10:34 a.m. Sept. 9, 2013 - 247WallSt.com
Oncolytics Drug Shrinks Tumors in 92% of Patients in Study 8:19 a.m. Sept. 9, 2013 - FOXBusiness
Oncolytics Biotech Announces Positive Final Tumour Response Data for US Phase 2 Study of REOLYSIN in Squamous Cell Lung Cancer 4:34 a.m. Sept. 9, 2013 - benzinga.com
Oncolytics Biotech: A Cancer Drug Pioneer Worth Looking Into 1:59 p.m. Aug. 9, 2013 - Seeking Alpha
Promising Data on ONCY's Reolysin - Analyst Blog 4:40 p.m. May 24, 2013 - Zacks.com
Oncolytics Announces First Stage of Metastatic Melanoma Phase 2 Trial Meets Primary Endpoint 4:41 a.m. May 22, 2013 - benzinga.com
Oncolytics Biotech's CEO Presents at 2013 Annual Meeting of Shareholders Conference (Transcript) 12:33 a.m. May 11, 2013 - Seeking Alpha
Oncolytics: A Failing Biopharma, Or An Opportune Buy? 2:15 a.m. April 8, 2013 - Seeking Alpha
Oncolytics Phase 2 Study of REOLYSIN Meets Primary Endpoint in Squamous Cell Lung Cancer 4:33 a.m. March 28, 2013 - benzinga.com

Oncolytics Biotech® Inc. to Present at the 25th Annual Piper Jaffray Healthcare Conference 6:30 a.m. Dec. 3, 2013 - PR Newswire
FDA Clearance, Management Changes, and Clinical Study Updates - Research Report on Illumina, Array, Oncolytics, Intrexon, and STERIS 8:00 a.m. Nov. 26, 2013 - PR Newswire
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Launches Investigation of ONCOLYTICS BIOTECH INC. for Possible Violations of Federal Securities Laws 1:29 p.m. Nov. 22, 2013 - BusinessWire
HOLX, GMCR, ONCY and ZNGA added to NASDAQ Active Stock Watch List at EPR 10:13 a.m. Nov. 21, 2013 - ACCESSWIRE
Oncolytics Biotech® Inc. Announces Positive Top-Line Data from REO 018 Randomized Study of REOLYSIN® in Head and Neck Cancers 6:00 a.m. Nov. 21, 2013 - PR Newswire
Oncolytics Biotech® Inc. Announces Third Quarter 2013 Results 6:30 a.m. Nov. 7, 2013 - PR Newswire
Oncolytics Biotech® Inc. Collaborators Present Positive Data Correlating Specific Biomarkers with Survival in NSCLC Patients Treated with REOLYSIN®, Carboplatin and Paclitaxel 5:30 a.m. Oct. 28, 2013 - PR Newswire
Oncolytics Biotech® Inc. Announces Progression Free Survival Data for Phase 2 Study of REOLYSIN® in Squamous Cell Lung Cancer 5:30 a.m. Oct. 22, 2013 - PR Newswire
Stockboard Custom Reports on Oncolytics Biotech Inc. and Valeant Pharmaceuticals International Inc. 8:04 a.m. Oct. 16, 2013 - ACCESSWIRE
Oncolytics Biotech Inc. Collaborators to Present Positive Clinical Trial Data at the 15th Annual World Conference on Lung Cancer 12:15 p.m. Oct. 1, 2013 - PR Newswire
RDInvesting Provides Investors with Free In-Depth Equity Reports on ONCY, RMTI, TEVA and VPHM 8:01 a.m. Sept. 16, 2013 - ACCESSWIRE
Biotech Firms Receive Orphan Drug Designations, Release Clinical Data, Achieve Goals, Enter Acquisitions & Forecast Revenues - Research Report on Aegerion, Oncolytics, Merrimack, Sangamo, and PDL 7:00 a.m. Sept. 12, 2013 - PR Newswire
Wall Street Fundamentals Releases New In-Depth Stock Reports on ACHN, BLRX, DSCO and ONCY 7:51 a.m. Sept. 10, 2013 - ACCESSWIRE
Media Advisory - Oncolytics Biotech® Inc. Announces Participation in Upcoming Conferences 4:00 p.m. Sept. 9, 2013 - PR Newswire
Oncolytics Biotech® Inc. Announces Positive Final Tumour Response Data for U.S. Phase 2 Study of REOLYSIN® in Squamous Cell Lung Cancer 5:30 a.m. Sept. 9, 2013 - PR Newswire
Media Advisory - Oncolytics Biotech® Inc. to Present at the 2013 Wedbush PacGrow Life Sciences Management Access Conference 4:00 p.m. Aug. 13, 2013 - PR Newswire
Lorus Therapeutics Appoints Dr. Brad Thompson, an Experienced Biotechnology Professional, to the Board of Directors 6:01 a.m. June 27, 2013 - Marketwire
Oncolytics Biotech? Inc. to Present at 2013 Jefferies Global Healthcare Conference 5:30 a.m. June 4, 2013 - PR Newswire
Oncolytics Biotech? Inc. Meets Primary Endpoint for First Stage of U.S. Phase 2 Metastatic Melanoma Trial 5:30 a.m. May 22, 2013 - PR Newswire
Media Advisory - Oncolytics Biotech? Inc. to Present at Bank of America Merrill Lynch Health Care Conference 5:30 a.m. May 14, 2013 - PR Newswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

BlueNord Signals Strategic Shift with Vår Energi Merger

BlueNord's Bold Move in the Energy Sector With the ink barely dry on their third-quarter results, BlueNord has dropped a bombshell: a merger approved with Vår Energi. This isn't just another page in their corporate books—it's a strategic pivot that could redefine their place within the oil and gas arena. Anybody keeping an eye on the energy sector right now should sit...

Auction Direct USA Offers Budget-Friendly Used Cars

Dollars and Sense: Affordable Cars in Raleigh Listen up, folks. These days, unless you're on the hunt for a fancy ride decked out with every bell and whistle, the idea of nabbing a car under ten grand almost sounds like a fairytale. But Auction Direct USA in Raleigh is making this dream a reality. That’s right, a whole fleet of used cars, all priced under $10,000, is...

Review Insurance Coverage After Major Life Changes

Why Life Changes Demand an Insurance Review The nitty-gritty of life doesn't sit still—marriages, babies, job changes, and home deals or steals each bring their own clutter to the table. One thing's for sure: when your life shifts, your insurance ought to keep pace. Insurance Agent Nick Hogan drops the dime in the latest HelloNation article, laying it bare why...

Insurify's AI Gateway: A New Era in Insurance Shopping

Insurify's Game-Changing AI Agent Gateway In the insurance world, Insurify's latest move feels like a bull charging through a ticker tape parade. This Cambridge-based pioneer unveiled its AI Agent Gateway, aiming to put consumers back in the driver's seat. By connecting digital assistant agents to its platform, Insurify's making insurance shopping a bit less like pulling...

Photocure's Q3 2026: Revenue Plateau and CFO Shakeup

The Bladder Cancer Scene: Steady as She Goes Sometimes, you look at numbers and find tranquility, like staring into still waters. That's the scene over at Photocure ASA with their latest Q3 results. Clocking in with revenues of NOK 134.2 million from their Hexvix®/Cysview® products, they're barely flinching from last year's NOK 134.1 million. Is it a victory or a...

Housing Transition: Unlocking the Trillion-Dollar Pathway

A Trillion-Dollar Balancing Act at COP31 The housing market: one giant balancing act, now with a trillion bucks at stake. The Sustainable Real Estate Forum (SREF) didn't hold back in their new white paper, "The Trillion-Dollar Housing Transition." They've outlined the monumental shift needed to get our housing not just affordable, but sustainable too. The Lay of the Land...

AST SpaceMobile Suit Seeks Lead Plaintiff by November 13

The Legal Rigmarole The market's got its knickers in a twist over AST SpaceMobile, folks. If you've been dabbling in NASDAQ:ASTS between March '25 and mid-July '26, it's time to perk up those ears. The legal eagles at Robbins Geller Rudman & Dowd LLP are rallying the troops for a class action lawsuit with you front and center. Deadline's looming on November 13, 2026, for...

Shareholder Lawsuit Targets Anavex Amid Falling Stock

Anavex Under Fire: Investor Rights at the Forefront Another day, another lawsuit makin' waves in that fragile sea called the stock market. This time, it's Anavex Life Sciences Corp. (NASDAQ: AVXL) getting dunked in the soup for allegedly misleading their investors, leaving a bunch of folks wringing their hands and wallets. What's the Beef with Anavex? We've got a class...

Federal Signal Acquires GVS, Boosts Vacuum Truck Lineup

Federal Signal's Latest Move in Vacuum Truck Arena A shakeup in the vacuum truck market? You bet. Federal Signal Corporation has made waves yet again by acquiring the lion's share of Global Vacuum Systems (GVS) assets and operations. We're talking a transaction valued at a hefty $29 million. Dishing Out the Dollars and Cents Now, what stirs the pot in this deal is the...

Navigating Investment Risk: Pre-Retirement Challenges

Finding the Right Investment Balance As retirement edges closer, the question often buzzing around like a relentless mosquito is: How much investment risk should we take? Investing ain't a one-size-fits-all game, and that becomes crystal clear when you're eyeing the golden years. There's a swath of choices to make, and Kevin Foreman, a financial advisor, rolls up his...